KR20070032537A - High density mineral salt and thereof manufacturing method - Google Patents
High density mineral salt and thereof manufacturing method Download PDFInfo
- Publication number
- KR20070032537A KR20070032537A KR1020050086865A KR20050086865A KR20070032537A KR 20070032537 A KR20070032537 A KR 20070032537A KR 1020050086865 A KR1020050086865 A KR 1020050086865A KR 20050086865 A KR20050086865 A KR 20050086865A KR 20070032537 A KR20070032537 A KR 20070032537A
- Authority
- KR
- South Korea
- Prior art keywords
- salt
- salinity
- sea water
- seawater
- molecular structure
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 94
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 57
- 239000011707 mineral Substances 0.000 title claims abstract description 57
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 235000010755 mineral Nutrition 0.000 claims abstract description 56
- 239000013535 sea water Substances 0.000 claims abstract description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 26
- 239000011780 sodium chloride Substances 0.000 claims abstract description 13
- 238000001704 evaporation Methods 0.000 claims abstract description 10
- 238000003860 storage Methods 0.000 claims abstract description 8
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 7
- 230000008859 change Effects 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000001694 spray drying Methods 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 230000008020 evaporation Effects 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 10
- 238000001035 drying Methods 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 235000005911 diet Nutrition 0.000 abstract description 2
- 239000004745 nonwoven fabric Substances 0.000 abstract description 2
- 230000000378 dietary effect Effects 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 99
- 239000011777 magnesium Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 206010061291 Mineral deficiency Diseases 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- -1 salt salts Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 102100038567 Properdin Human genes 0.000 description 1
- 108010005642 Properdin Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 239000011425 bamboo Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006227 byproduct Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000037345 metabolism of vitamins Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Seasonings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
도 1a 및 도 1b는 본 발명에 따른 미네랄 소금의 입자 크기를 보인 사진,1a and 1b is a photograph showing the particle size of the mineral salt according to the present invention,
도 2는 본 발명에 따른 미네랄 소금 제조방법을 보인 플로우챠트.Figure 2 is a flow chart showing a mineral salt manufacturing method according to the present invention.
본 발명은 고농도 미네랄 소금 및 그 제조방법에 관한 것으로, 보다 상세하게는 인체에 결핍되기 쉬운 다양한 미네랄을 고농도로 농축하고 체내 흡수가 용이한 구조를 갖도록 하여 식생활 개선 및 건강증진을 도모할 수 있도록 한 고농도 미네랄 소금 및 그 제조방법에 관한 것이다.The present invention relates to a high concentration mineral salt and a method for manufacturing the same, and more particularly, to concentrate the various minerals that are easily deficient in the human body to a high concentration and to have a structure that is easy to absorb in the body to improve the diet and health promotion It relates to a high concentration mineral salt and a method for producing the same.
일반적으로, 소금은 인체에 흡수되어 체액의 삼투압을 조절하고, 산과 염기의 평형에 관여하는 신경자극 물질일 뿐만 아니라 소화액을 구성하는 중요성분이며 나아가 식품의 맛을 조절하는 조미료이기도 하다.In general, salt is absorbed by the human body to control the osmotic pressure of body fluids, and is not only a neurostimulating substance involved in the equilibrium of acids and bases, but also an important component of digestive fluids, and is also a seasoning that controls food taste.
즉, 소금은 체내에서 세포막의 전압조절에서부터 혈압조절 등 신체기능 어디에나 관련되어 있고, 특히 Na+은 체액의 삼투압과 혈장의 부피유지, 신경흥분, 근육 수축 및 영양소의 이동에 매우 중요한 역할을 하며, 반면에 과다할 경우에는 고혈압의 원인이 되므로 주의하여야 한다.In other words, salt is involved in body functions such as voltage regulation of cell membranes and blood pressure in the body.In particular, Na + plays a very important role in osmotic pressure of body fluids, plasma volume maintenance, nerve excitement, muscle contraction, and nutrient movement. On the other hand, excessive blood pressure may cause high blood pressure.
이러한 소금은 보통 해수로부터 만들어지는데 해수에는 여러가지 인체에 유용한 성분인 칼륨, 칼슘, 마그네슘, 아연, 철, 인, 나트륨, 망강 등의 미네랄 성분이 포함되어 있는 반면에 인체에 유해한 성분인 염화마그네슘, 염산, 황산 등도 함유되어 있다.These salts are usually made from seawater, which contains minerals such as potassium, calcium, magnesium, zinc, iron, phosphorus, sodium, and manganese, which are useful to the human body, while magnesium chloride and hydrochloric acid are harmful to the human body. And sulfuric acid.
따라서, 해수를 햇볕으로 수분을 증발시켜 만든 천일염이나 해수를 가열하여 건조시키거나 해수를 분사시키면서 열풍으로 건조시켜 만든 해수염은 해수의 오염 등으로 불순물이 많이 함유되어 있으므로 이를 정제해야 비로소 식염으로 사용할 수 있게 된다.Therefore, sea salt made by evaporating moisture in the sun or sea water heated or dried by hot air while spraying sea water contains a large amount of impurities due to contamination of sea water. It becomes possible.
나아가, 가정용 식염을 비롯하여 공장용 염에 이르기까지 다양한 용도의 가공소금이 개시되어 있는 바, 예컨대 재제염(일명 '백염' 혹은 '꽃소금'), 맛소금(기계염을 가공한 소음으로 소금 생금, 구운소금, 죽염 등), 세척염, 부산물염(회수염), 정제소금(깨소금, 볶은 소금, 글루탐산나트륨이나 복합화학조미료를 피복시킨 소금 등) 등이 그것이다.Furthermore, processed salts have been disclosed for various purposes, ranging from domestic salts to factory salts, for example, re-salt salts (also known as 'white salt' or 'flower salt'), salt salts (salt salt, roasted salt, Bamboo salts), washing salts, by-product salts (recovering salts), refined salts (seed salt, roasted salt, salts coated with sodium glutamate or a complex chemical seasoning).
그러나, 이들 가공소금들은 그 가공과정에서 미네랄이 소실되거나 혹은 남아 있다고 하더라도 체내 흡수에 적당하지 못한 분자구조와 크기로 변형되어 버리기 때문에 인체에 유익한 수많은 미네랄이 포함된 해수를 원료로 하여 만들어진 소금을 통한 자연스러운 미네랄 보충이 어렵게 되고, 이는 소금의 많은 유용성에도 불구하고 미네랄 결핍이라는 현상을 유발하게 된다(여기에서의 미네랄 결핍은 인위적 인 미네랄 보충의 경우는 제외한 것이다).However, these processed salts are transformed into molecular structures and sizes that are not suitable for absorption in the body even if minerals are lost or remain in the process, and salts made from salt water made from seawater containing numerous minerals that are beneficial to the human body. Natural mineral supplementation becomes difficult, which leads to the phenomenon of mineral deficiency despite the many usefulness of salt (mineral deficiency here, except for artificial mineral supplementation).
이때, 미네랄은 공지된 바와 같이 체내의 물질대사에 관여하는 효소의 재료로 쓰이는 중요한 물질로서 그 필요량이 아무리 적은 양이라 하더라도 그것이 보급되지 못하면 효소를 만들지 못하게 되고, 결국 물질대사가 어렵게 되어 건강을 유지할 수 없게 된다.At this time, the mineral is an important substance used as an enzyme material involved in metabolism in the body, no matter how small the amount required, if it is not spread, it will not be able to make enzymes, eventually metabolism becomes difficult to maintain health It becomes impossible.
따라서, 소금만의 섭취를 통해 미네랄의 체내 흡수를 가능케 하여 미네랄 결핍현상을 자연스럽게 해소시킬 수 있는 새로운 형태의 소금이 절실히 요청되고 있는 실정이다.Therefore, there is an urgent need for a new type of salt that can relieve mineral deficiency naturally by allowing the absorption of minerals through the intake of salt alone.
본 발명은 상술한 바와 같은 요청에 적극적으로 부응하기 위하여 창출된 것으로, 해수 및 갯벌에 포함된 다수의 미네랄을 변형없이 소금화시키되 외적부가없이 고농도로 농축시킴은 물론 체내 흡수에 최적합한 형태의 분자구조와 크기를 갖도록 하여 그 유용성을 극대화시킨 고농도 미네랄 소금 및 그 제조방법을 제공함에 주된 목적이 있다.The present invention was created in order to actively respond to the request as described above, salts of many minerals contained in seawater and tidal flats without modification, but concentrated to high concentrations without external additions, as well as molecules of the form suitable for absorption in the body The main purpose is to provide a high concentration mineral salt and a method for producing the same by having a structure and size to maximize its usefulness.
본 발명은 상기한 기술적 과제를 달성하기 위하여, 공지의 천연 소금을 구성하는 성분중, Mg가 2.80~5.16중량%, Na와 Cl의 합이 90중량% 이하로 유지되도록 조성된 고농도 미네랄 소금을 제공함에 그 기술적 특징이 있다.The present invention, in order to achieve the above technical problem, of the components constituting the known natural salt, Mg is 2.80 ~ 5.16% by weight, and provides a high concentration mineral salt is configured so that the sum of Na and Cl is 90% by weight or less Has its technical characteristics.
또한, 본 발명은 갯벌에 일정크기의 저수지를 만들고 해수를 유입시켜 저장하는 단계와; 저장된 해수를 염도 2~3‰에 이를때 까지 자연증발시키는 단계와; 2~3‰의 염도를 갖는 해수를 1km 이상 경사형성된 염판상에 흘려 보내는 형태로 순환시켜 자연증발을 통해 염도 20‰까지 조절하는 단계와; 20‰의 염도를 갖는 해수를 보관탱크를 바꾸어 가면서 보관탱크내에 장시간 체류시켜 침전을 유도함과 동시에 부직포 소재의 필터를 통해 여과 이동시켜 염도 25‰까지 농축시키는 단계와; 농축된 25‰의 해수를 나노프레쉬를 이용하여 교반시켜 NaCl, 미네랄의 분자구조를 고분자구조에서 저분자구조로 변화시키는 단계와; 분자구조가 변화된 농축 해수를 스프레이드라이어를 이용하여 분사 건조시켜 미네랄 소금을 생성하는 단계를 포함하여 구성된 고농도 미네랄 소금 제조방법을 제공함에도 그 기술적 특징이 있다.In addition, the present invention comprises the steps of making a reservoir of a certain size on the tidal-flat and inflowing and storing sea water; Evaporating the stored seawater until salinity reaches 2˜3 ‰; Circulating the seawater having a salinity of 2˜3 ‰ in the form of flowing on the inclined salt plate of 1 km or more to adjust the salinity to 20 ‰ through natural evaporation; Concentrating the salt water having a salinity of 20 ‰ in the storage tank while changing the storage tank for a long time to induce sedimentation and filtration through a filter of nonwoven material to concentrate the salinity to 25 ‰; Stirring the concentrated 25 ‰ seawater using nanofresh to change the molecular structure of NaCl and minerals from a polymer structure to a low molecular structure; There is also a technical feature to provide a method for producing a concentrated mineral salt comprising the step of generating a mineral salt by spray drying the concentrated seawater with a changed molecular structure using a spray dryer.
이하에서는, 첨부도면을 참고하여 본 발명에 따른 바람직한 실시예에 대해 상세히 설명하기로 한다.Hereinafter, with reference to the accompanying drawings will be described in detail a preferred embodiment according to the present invention.
본 발명에 따른 미네랄 소금은 해수에 포함된 미네랄 성분은 물론 갯벌에 함유되어 있는 다양한 종류의 미네랄도 함께 고농도로 농축되어 이루어진 것으로 그 성분조성은 다음과 같다.The mineral salt according to the present invention is composed of various kinds of minerals contained in tidal flats as well as minerals contained in seawater, and the composition is as follows.
본 발명 미네랄 소금은 중량%로, Na:36.67%, Cl:53.28%, Si:0.12%, P:0.58%, S:2.91%, K:0.24%, Ca:0.04%, Fe:0.11%, Zn:0.32%, Ge:0.36%, As:0.21%의 성분조성, 즉 통상의 소금이 갖는 성분조성중 Mg의 함유율이 2.80~5.16중량% 까지 변화될 수 있는 것에 특징이 있으며, 이러한 변화시 Na와 Cl의 성분함량에 변화가 생기게 되어 전체적인 성분조성은 100에 이르게 된다.The mineral salt of the present invention is in weight%, Na: 36.67%, Cl: 53.28%, Si: 0.12%, P: 0.58%, S: 2.91%, K: 0.24%, Ca: 0.04%, Fe: 0.11%, Zn : 0.32%, Ge: 0.36%, As: 0.21%, that is, the content of Mg in the composition of ordinary salt can be changed to 2.80 ~ 5.16% by weight, Na and Cl Changes in the component content of lead to a total composition of 100.
또한, 상기와 같은 성분조성으로 이루어진 본 발명 미네랄 소금은 수소이온농도(pH)가 9.6으로 알칼리성이고, 그 입자의 크기는 7㎛ 정도를 가지며, 이 소금 에 붙어 있는 미네랄은 대략 1.5㎚ 정도의 초미세한 크기를 유지하도록 구성된다.In addition, the mineral salt of the present invention composed of the above-described composition is alkaline with a hydrogen ion concentration (pH) of 9.6, the particle size of which is about 7 μm, and the mineral attached to the salt is about 1.5 nm in size. It is configured to maintain a fine size.
이와 같이, 본 발명 미네랄 소금은 NaCl이 대략 90% 이하로 유지되고, 나머지는 미네랄, 특히 Mg이 강제로 다량함유되게 조성되어 있어, 본 발명에 대비되는 종래 소금들 이를테면, 제재소금(NaCl:98.34%), 기계염(NaCl:98.48%), 알카리소금(NaCl:97.8%), 구운소금(NaCl:98.17%), 천일염(NaCl:96.13%) 들과 성분상 현격한 차이를 보인다.As such, the mineral salt of the present invention maintains approximately 90% or less of NaCl, and the remainder is forcibly contained in a large amount of minerals, in particular Mg, such as conventional salts, such as mill salt (NaCl: 98.34 %), Mechanical salt (NaCl: 98.48%), alkaline salt (NaCl: 97.8%), roasted salt (NaCl: 98.17%), and natural salt (NaCl: 96.13%).
뿐만 아니라, 도 1a,b에 도시된 바와 같이, 본 발명 미네랄 소금은 그 입자크기가 대략 7㎛ 정도여서 그에 붙어있는 미네랄의 직경이 대략 1.5㎚가 되므로 체내 세포에 흡수되기에 최적합한 상태를 이루고 있으나 상술한 종래 소금들은 소금 자체의 크기가 500㎛에 이르고 있어 미네랄이 포함되어 있다고 하더라도 그 직경이 커 체내 흡수가 용이치 못하고, pH의 경우도 본 발명 미네랄 소금은 인체 흡수에 적당한 알카리성(pH:9.6)을 유지하고 있음에 반해 종래 재제염(꽃소금)은 pH 6.38, 기계염(예:한주소금)은 pH:6.21, 천일염(굵은소금)은 pH:6.25를 유지하고 있어 본 발명 미네랄 소금과 현격한 차이를 보이고 있음을 확인할 수 있다.In addition, as shown in Figures 1a, b, the mineral salt of the present invention has a particle size of about 7㎛ the diameter of the mineral attached to it is approximately 1.5nm, so that the optimal state to be absorbed by the cells in the body However, the above-described conventional salts have a salt size of 500 μm, and even though minerals are included, their diameters are not easy to absorb in the body, and even in the case of pH, the salt of the present invention is suitable for alkaline absorption (pH: 9.6), while the conventional re-salting (flower salt) maintains a pH of 6.38, mechanical salt (e.g. Hanju), pH: 6.21, and natural salt (coarse salt) of pH: 6.25, which is significantly different from the mineral salt of the present invention. You can see that it shows.
여기에서, 마그네슘은 에너지 생성, 신경기능 조절, 장에서의 칼슘 흡수 조력, 비타민 C, B, E의 대사 조력, 특히 B6의 대사에 중요한 역할을 하는 미네랄의 일종으로 체내 약 0.1%를 차지하며 칼슘과 함께 뼈에 함유되어 있고, 근육과 신경의 기능을 유지하며, 에너지를 발생시키고 단백질 합성의 촉매로 작용하는 원소로서 칼슘, 칼륨, 나트륨 등 다른 무기염류의 대사에도 영향을 미치므로 마그네슘이 체내에 부족시 질병에 걸리거나 기존의 질병이 악화될 수 있다.Here, magnesium is a type of mineral that plays an important role in energy production, nerve function control, calcium absorption in the intestine, metabolism of vitamins C, B, and E, especially B6. It is contained in bones, maintains muscle and nerve function, generates energy and acts as a catalyst for protein synthesis. It also affects the metabolism of other inorganic salts such as calcium, potassium and sodium. Insufficiency can lead to disease or exacerbation of existing diseases.
하지만, 통상적인 소금, 즉 제제염, 기계염, 천일염 등에서는 해수에 포함된 마그네슘의 입자가 커 미네랄 형태로 함유되어 있다손 치더라도 체내에 흡수되지 못하고, 기타 여러가지 정책적 혹은 제조상의 이유에 의해 일부러 함유시키지 않고 있기도 하다.However, in ordinary salts, such as preparation salts, mechanical salts, and sun salts, the particles of magnesium contained in seawater are largely contained in mineral form, and even if damaged, they cannot be absorbed into the body and are deliberately contained for various policy or manufacturing reasons. Not even let it.
본 발명에서는 이와 같이 매우 중요한 기능을 담당하는 Mg을 일정함량으로 소금에 함유되도록 함으로써 부족에 의한 결핍을 해소토록 한 것이며, 이때 그 성분조성을 상기와 같이 한정하는 이유는 마그네슘이 2.80 중량% 이하로 첨가되면 그 효과가 미비하고, 5.16 중량% 이상으로 첨가되면 프로파진(properdin) 효소계의 비특이적 생체방위 작용이 강하게 촉진되어 혈액에 좋지 않은 영향을 미치므로 상기와 같은 조성범위로 한정되어 함유됨이 특히 바람직하다.In the present invention, Mg, which plays such a very important function, is contained in the salt in a constant amount to eliminate deficiency due to lack, and the reason for limiting the composition of the composition as described above is that magnesium is added at 2.80% by weight or less. If the effect is insignificant, and when added at 5.16% by weight or more, the non-specific biodefense action of the properdin enzyme system is strongly promoted, which adversely affects the blood, and thus it is particularly preferably limited to the above composition range. Do.
이와 같은 본 발명 미네랄 소금은 도 2에 도시된 플로우챠트를 따라 제조된다.Such mineral salts of the present invention are prepared according to the flowchart shown in FIG. 2.
먼저, 갯벌에 일정크기의 저수지를 만들고, 이 저수지로 해수가 유입될 수 있도록 수로를 만든 다음 15일을 주기로 반복되는 만조때에 수로를 폐쇄하고 있던 도어를 열어 해수의 일부를 상기 저수지로 유입시켜 저장하는 단계를 거친다(S100).First, a reservoir of a certain size is created on the tidal flat, and a channel is formed so that seawater can flow into the reservoir, and then a part of the seawater is introduced into the reservoir by opening a door that is closed at the time of high water which is repeated every 15 days. The step of storing (S100).
이어, 저장된 해수는 자연 증발에 의해 그 염도가 2~3‰에 이르게 되고, 불용분이 어느 정도 침전되게 된다(S110).Subsequently, the stored seawater reaches 2 to 3 ‰ of salinity by natural evaporation, and insoluble matter is precipitated to some extent (S110).
저장된 해수의 염도가 2~3‰에 이르면 불용분의 일부가 침전된 해수를 갯벌에 만든 염전 내부로 유입시키는 단계를 거친다(S120,S130).When the salinity of the stored seawater reaches 2˜3 ‰, a portion of the insoluble matter is introduced into the salt field in the tidal flat (S120, S130).
이때, 해수의 염도가 2~3‰에 이르지 못하면 상기 S110 단계로 피이드백되어 그 염도가 2~3‰에 이를때까지 지속적인 증발 및 침전작용이 수행된다.At this time, if the salinity of seawater does not reach 2˜3 ‰, it is fed back to the step S110 and continuous evaporation and precipitation are performed until the salinity reaches 2˜3 ‰.
상기 S120 단계를 통해 염전 내부로 유입된 해수는 그 염도가 20‰에 이를때까지 지속적인 조절과정을 거쳐 보관탱크에 저장되게 된다(S140).The seawater introduced into the saltfield through the step S120 is stored in the storage tank through the continuous adjustment process until the salinity reaches 20 ‰ (S140).
여기에서, 염도를 20‰까지 조절하는 과정은 경사지게 형성된 염전을 대략 1km에 걸쳐 형성하고, 상기 염전에 염판을 배설하여 순환되게 하되 순환되는 유량을 적절히 조절함으로써 햇볕과 바람을 이용한 자연증발에 의해 이루어지도록 함이 바람직하다.Here, the process of adjusting the salinity to 20 ‰ is made by forming a sloped salt over about 1km, and by discharging the salt plate to be circulated, and by the natural evaporation using the sun and wind by appropriately adjusting the circulating flow rate It is desirable to make it.
이는 갯벌 위에서의 자연증발을 이용함으로써 천연에너지인 태양열을 이용하게 되므로 연료비를 절감시킴은 물론 자연스럽게 미네랄 함유량을 증가시킬 수 있기 때문이다.This is because by using the natural evaporation on the tidal flat to use the solar energy, natural energy, because it can reduce the fuel cost and naturally increase the mineral content.
상기 S140 단계를 거쳐 염도 20‰를 유지하는 해수를 가공하여 염도 25‰까지 농축함으로써 포화함수를 생성시킨다(S150).By processing the seawater maintaining the salinity 20 ‰ through the step S140 to produce a saturated function by concentrating to the salinity 25 ‰ (S150).
이때, 염도를 향상시켜 농축하는 과정은 보관탱크를 바꾸어 가면서 장기간, 바람직하게는 1달 동안 해수를 체류시킴으로써 자연스럽게 염도를 향상시키게 되며, 동시에 불용분의 지속적인 침전을 유도하게 된다.At this time, the process of concentrating by improving salinity improves salinity naturally by retaining seawater for a long period of time, preferably one month, while changing the storage tank, and at the same time, leads to continuous precipitation of insoluble content.
또한, 해수를 다른 보관탱크로 이동시킬 때에 부직포 소재의 필터를 이용하여 여과함으로써 불순물도 제거할 수 있게 된다.In addition, when the seawater is moved to another storage tank, it is possible to remove impurities by filtering using a filter made of a nonwoven material.
상기 S150 단계를 거쳐 해수의 염도가 25‰에 도달하게 되면 이를 교반시켜 고분자의 NaCl 구조를 저분자화시키는 단계를 수행하게 된다(S160).When the salinity of the seawater reaches 25 ‰ through the step S150 is stirred to perform the step of low molecular weight NaCl structure of the polymer (S160).
즉, 나노프레쉬(Nano Fresh)를 이용하여 대략 3시간 정도 교반시킴으로써 해수와 공기의 혼합을 촉진시켜 NaCl의 분자구조를 고분자구조에서 저분자구조로 변화시키게 된다.In other words, by stirring for about 3 hours using Nano Fresh to promote the mixing of seawater and air to change the molecular structure of NaCl from high molecular structure to low molecular structure.
여기에서, 나노프레쉬란 네가트론 촉매체로 구성되어 있으며, 이 촉매체는 4~14 미크론의 전자파를 영구적으로 발생시키는 물질입니다.Here, nanofresh is composed of negative electron catalyst, which is a material that permanently generates 4 ~ 14 micron electromagnetic waves.
일반적으로 4~14 미크론의 파장대역의 전자파는 생물에 가장 흡수되기 쉬운 성질을 갖는 것으로 생물의 체내에서 물질적으로 총합적, 합성적으로 작용되기 때문에 소위 "육성광선(育成光線)"이라고도 불려지고 있으며, 이에 따라 동ㆍ식물의 세포를 활성화하거나, 단백질을 합성하거나, 오염수를 정화하는 등 자연계에서 중요한 역할을 하는 기초물질의 하나이다.In general, electromagnetic waves in the wavelength range of 4 to 14 microns are most easily absorbed by living organisms, and are called so-called "growth rays" because they act physically and synthetically in living organisms. As a result, it is one of the basic substances that play an important role in nature, such as activating cells of plants and plants, synthesizing proteins, and purifying contaminated water.
나아가, 육성광선은 물체나 동ㆍ식물의 세포에 좋은 영향을 주는 미약에너지 치고는 가장 강한 에너지를 갖는 것으로 확인되고 있다.Furthermore, growing rays have been confirmed to have the strongest energy for weak energy that has a good effect on the cells of objects, animals and plants.
한편, 물은 통상 물분자(H2O) 단독으로 존재하지 않으며, 실상은 포도송이처럼 덩이 상태로 존재하기 때문에 이것을 물의 클러스터(Cluster)라 부르고 있다.On the other hand, water does not normally exist in water molecules (H 2 O) alone, and in fact, because they exist in a lump state like grape clusters, this is called a cluster of water (Cluster).
대체로 물은 36~37개의 클러스터가 되어 존재하고 있는데 오염된 물은 200~300개 정도, 심하게 부패된 폐수인 경우 1000개 이상으로 뭉쳐져 있으나 나노프레쉬 내에서 발생하는 50,000~120,000㏄/ℓ의 음이온과 미약에너지인 전자파 4~14 미크론의 육성광선은 물의 분자를 강력하게 여기시켜 진동상태를 만들고, 104.5°였던 물 분자의 각도를 95°혹은 180°로 변화시켜 5~6개 정도의 작은 클러 스터 형태로 만들어 자화음이온수를 만들게 된다.Generally, water is present in 36 ~ 37 clusters. Contaminated water is composed of 200 ~ 300, and more than 1000 in case of severely decayed wastewater, but 50,000 ~ 120,000㏄ / ℓ anion generated in nanofresh Weak energy of 4 ~ 14 microns of electromagnetic waves, which is a weak energy, strongly excites water molecules to create a vibration state, and changes the angle of water molecules from 104.5 ° to 95 ° or 180 ° to form 5 ~ 6 small clusters. It will make magnetized negative ionized water.
이때, 클러스터가 6개 일 때를 흔히 "6각수"라고 하며, 이는 섭씨 5℃ 부근에서 많이 나타난다.At this time, when there are six clusters is often referred to as "hexagon", which appears a lot around 5 ℃ Celsius.
이와 같이 나노프레쉬를 통해 NaCl의 구조를 6각수 형태의 작은 클러스터들로 이루어진 구조로 변화시키게 된다.As such, the structure of NaCl is changed to a structure composed of small clusters of hexagonal forms through nanofresh.
이후, 스프레이드라이어를 이용하여 해수를 분사 건조시킴으로써 미네랄 소금을 제조하게 되며, 제조된 미네랄 소금은 포장 및 출하되게 된다(S170,S180).Thereafter, by spray drying the sea water using a spray dryer to prepare a mineral salt, the prepared mineral salt is packaged and shipped (S170, S180).
여기에서, 상기 스프레이드라이어는 디스크형 혹은 노즐형이 될 수 있으며, 해수가 분사되면서 건조되는 공간은 밀폐되어 있고 대략 180~300℃의 온도를 유지하고 있으며, 설정된 분사압력으로 분사되게 된다.Here, the spray dryer may be a disk type or a nozzle type, the space to be dried while the sea water is sprayed is maintained at a temperature of approximately 180 ~ 300 ℃, and is sprayed at a set injection pressure.
이때, 상기 분사압력은 생성될 소금의 수분에 관계되는 것으로 제조하고자 할 미네랄 소금의 입자 크기에 따라 다양한 값으로 달라질 수 있기 때문에 특별히 한정하지는 않는다.At this time, the injection pressure is not particularly limited because it may vary in various values depending on the particle size of the mineral salt to be produced to be related to the moisture of the salt to be produced.
아울러, 건조시 상기 온도로 한정하는 이유는 대략 180℃ 이하가 되면 알카리성을 유지하기 힘들고, 300℃를 넘게 되면 알카리성이 강하게 되므로 상기 온도범위로 한정하는 것이 바람직하며, 특히 바람직하기로는 250℃ 정도 일 때 약알카리에 가장 적당하다.In addition, the reason for limiting to the temperature at the time of drying it is difficult to maintain the alkalinity when the temperature is about 180 ° C or less, and the alkalinity becomes stronger when it exceeds 300 ° C, preferably limited to the above temperature range, particularly preferably about 250 ° C When it is most suitable for weak alkali.
이하, 실시예에 대하여 설명하기로 한다.Hereinafter, the embodiment will be described.
[실시예]EXAMPLE
본 발명 제조방법에 따라 미네랄 소금을 제조하였다.Mineral salt was prepared according to the preparation method of the present invention.
이때, 부직포 필터는 5㎝ 두께를 사용하였고, 염도는 25‰, 나노프레쉬는 3시간동안 5톤의 소금물을 교반시켰다.At this time, the non-woven fabric filter was used 5cm thickness, salinity 25 ‰, nanofresh was stirred for 5 tons of brine for 3 hours.
이어, 로터리 아토마이저(Rotary Atomizer) 스프레이 드라이어(디스크형)를 이용하여 250℃의 건조 온도를 유지한 채 아토마이저(33,000rpm)에 피드펌프를 사용하여 시간당 5ℓ의 소금물을 분사하여 본 발명 미네랄 소금을 제조하였다.Then, the mineral salt of the present invention by spraying 5 L of salt water per hour using a feed pump to the atomizer (33,000rpm) while maintaining a drying temperature of 250 ℃ using a rotary atomizer spray dryer (disk type) Was prepared.
제조된 미네랄 소금의 pH는 9.6이었으며, 주사전자현미경을 통해 관찰해본 결과 도 3에서와 같이, 단위 클러스터들이 거의 6을 이루어 6각수에서와 같은 구조로 소금, 미네랄의 분자구조가 변화되어 있는 것을 확인하였다.The pH of the prepared mineral salt was 9.6. As a result of observing with a scanning electron microscope, as shown in FIG. 3, the unit clusters were almost 6, and the molecular structure of salt and mineral was changed to the same structure as in hexagonal water. It was.
나아가, 분자구조의 변화과정에서 소금의 입자가 7 마이크로 정도로 만들어짐으로써 그에 붙어 있는 미네랄의 직경이 약 1.5 나노미터의 크기로 초미세화되어 다량의 미네랄이 함유되어 있음도 확인하였는 바, 이를 하기한 표 1에 종래 소금과 대비하여 나타내었다.Furthermore, in the process of changing the molecular structure, the salt particles were made to be about 7 micro, so that the diameter of the mineral attached thereto was about 1.5 nanometers in size, so that it contained a large amount of minerals. Table 1 shows the conventional salt.
상기 표 1에서와 같이, 본 발명에 따른 미네랄 소금은 일반 가공소금에 비해 미네랄의 크기가 체내에 흡수되기에 최적합한 상태를 이루고 있음을 확인할 수 있었고, 또한 약알카리성을 띠고 있어 인체 흡수에 매우 적당함을 확인하였다.As shown in Table 1, the mineral salt according to the present invention was confirmed that the size of the mineral compared to the general processed salt is in the optimal state to be absorbed in the body, and also has a weak alkali, very suitable for human absorption It was confirmed.
이상에서 상세히 설명한 바와 같이, 본 발명에 따르면 해수와 갯벌에 포함된 다양한 종류의 미네랄을 변형없이 소금에 함유시킬 수 있어 소금의 섭취만으로도 자연스럽게 다종류의 미네랄이 인체에 흡수되게 함으로써 미네랄 결핍의 문제를 해소하고, 나아가 체내 흡수에 최적합한 크기를 갖도록 하여 원활한 흡수작용이 일어나도록 하여 주는 효과도 제공하게 된다.As described in detail above, according to the present invention, various kinds of minerals contained in seawater and tidal-flat can be contained in salt without modification, so that the mineral deficiency problem is naturally absorbed by the human body only by intake of salt. It also provides an effect of smoothing the absorption by causing the solution to have a size that is optimal for absorption in the body.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050086865A KR100761896B1 (en) | 2005-09-16 | 2005-09-16 | High density mineral salt manufacturing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050086865A KR100761896B1 (en) | 2005-09-16 | 2005-09-16 | High density mineral salt manufacturing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20070032537A true KR20070032537A (en) | 2007-03-22 |
| KR100761896B1 KR100761896B1 (en) | 2007-10-04 |
Family
ID=41560520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020050086865A KR100761896B1 (en) | 2005-09-16 | 2005-09-16 | High density mineral salt manufacturing method |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100761896B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100860846B1 (en) * | 2007-04-16 | 2008-09-30 | 주식회사 태평소금 | Granulated minerals salt manufacturing method |
| KR100860847B1 (en) * | 2007-04-16 | 2008-09-30 | 주식회사 태평소금 | Method for manufacturing natural salt |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101319835B1 (en) | 2012-10-25 | 2013-10-17 | 김순남 | The manufacturing method to gain mineral salt using filter |
| KR20220036600A (en) | 2020-09-16 | 2022-03-23 | 장순원 | A Manufacturing Method Of Solar Salt |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07170936A (en) * | 1993-12-21 | 1995-07-11 | Japan Tobacco Inc | Production of mineral-containing salt |
-
2005
- 2005-09-16 KR KR1020050086865A patent/KR100761896B1/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100860846B1 (en) * | 2007-04-16 | 2008-09-30 | 주식회사 태평소금 | Granulated minerals salt manufacturing method |
| KR100860847B1 (en) * | 2007-04-16 | 2008-09-30 | 주식회사 태평소금 | Method for manufacturing natural salt |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100761896B1 (en) | 2007-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DileepKumar et al. | A review on the synthesis and properties of hydroxyapatite for biomedical applications | |
| Buljan Meić et al. | Comparative study of calcium carbonates and calcium phosphates precipitation in model systems mimicking the inorganic environment for biomineralization | |
| Miller et al. | Testing of Brushite (CaHPO 4· 2 H 2 O) in Synthetic Biomineralization Solutions and In Situ Crystallization of Brushite Micro‐Granules | |
| KR100761896B1 (en) | High density mineral salt manufacturing method | |
| EP3490936B1 (en) | Habit modified crystals of zinc oxide | |
| Cheng et al. | Overview of structure, function and integrated utilization of marine shell | |
| Dameron et al. | Peptide-mediated formation of quantum semiconductors | |
| CN111034720A (en) | Preparation method of zinc oxide-metal organic framework composite antibacterial material | |
| KR20220032214A (en) | A method for manufacturing calcium carbonate by using seawater and calcinated shells, and the calcium carbonate and calcium agent thereof | |
| Ikoma et al. | Drug-supported microparticles of calcium carbonate nanocrystals and its covering with hydroxyapatite | |
| KR20180077662A (en) | Porous Mineral Manufacturing Method and Solubilized Porous Mineral Composition Manufacturing Method Using It | |
| KR100860847B1 (en) | Method for manufacturing natural salt | |
| KR100821385B1 (en) | Manufacturing method of organic mineral salts by using contained in deep sea water mineral salts | |
| KR100860846B1 (en) | Granulated minerals salt manufacturing method | |
| KR101907408B1 (en) | Manufacturing Method Of Calcium Phosphate Using Eggshell And Phosphate-ammonia solution | |
| JPWO2005055718A1 (en) | Silver-carrying particles and method for producing the same | |
| KR100821387B1 (en) | Manufacturing method of a mineral additives from deep sea water | |
| JP2006231137A (en) | Negatively ionized water | |
| KR101319835B1 (en) | The manufacturing method to gain mineral salt using filter | |
| CN104667253A (en) | Crocodile nano-polypeptide and preparation method thereof | |
| CN104399126A (en) | Preparation method of nano composite material through blending carbonate-ion-doped hydroxy apatite and polymethyl methacrylate | |
| KR101767843B1 (en) | The manufacture method of the table salt from deep sea water | |
| Nouri et al. | Review on biological synthesis of nano-hydroxyapatite and its application in nano-medicine | |
| KR100665892B1 (en) | Manufacturing method of clean salt from deep sea water or deep sea rock floor water | |
| WO2002081383A1 (en) | Far infrared ray radiant wave water and method of manufacturing the radiant wave water |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| G170 | Publication of correction | ||
| FPAY | Annual fee payment |
Payment date: 20120626 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20130703 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20140917 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20160901 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20170727 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20180918 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20190905 Year of fee payment: 13 |